Jan 20, 2021 • 8:05 am EST Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
Nov 12, 2020 • 8:05 am EST Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Nov 10, 2020 • 7:05 am EST Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
Nov 9, 2020 • 8:05 am EST Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
Nov 3, 2020 • 8:05 am EST Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
Oct 23, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
Oct 21, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
Oct 8, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
Oct 6, 2020 • 7:05 am EDT Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
Sep 8, 2020 • 7:05 am EDT Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis